Roche acquires Ariosa diagnostics

December 08, 2014 | Monday | News | By BioSpectrum Bureau

Roche acquires Ariosa diagnostics

Ariosa's proprietary Harmony Prenatal Test has been validated to CLIA requirements

Ariosa's proprietary Harmony Prenatal Test has been validated to CLIA requirements

Roche has announced the acquisition of Ariosa Diagnostics, a molecular diagnostics testing service provider that provides a highly targeted and accurate non-invasive prenatal testing (NIPT) service through their CLIA laboratory using cell-free DNA (cfDNA) technology.

Ariosa's proprietary Harmony Prenatal Test has been validated to CLIA requirements by a robust clinical data set and supported by clinical studies in more than 22,000 women of all ages and risk categories.

"The acquisition of Ariosa is another example of Roche's commitment to advanced molecular diagnostics. Circulating cfDNA has the promise of providing early diagnostic information through a simple blood test in many important segments including pregnancy, cancer and transplantation, aligning with our strategy in personalised healthcare and commitment to setting new standards of care," said Mr Roland Diggelmann, COO, Roche Diagnostics Division.

"We are thrilled to join forces with Roche to continue in our commitment to bringing forward high quality and affordable genetic testing that positively impacts the medical care of patients around the world," said Mr Ken Song MD, chief executive officer, Ariosa.

The closing of the transaction is expected to take place in December, 2014.

 

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy